University of Chicago President Robert Zimmer recently awarded named professorships to two Department of Medicine faculty effective January 1, 2020:  Vineet Arora, MD (General Internal Medicine) and Lucy Godley, MD, PhD (Hematology/Oncology). Dr. Arora, an academic hospitalist and medical educator who specializes in improving the learning environment for medical trainees and the quality, safety and experience of care delivered to hospitalized adults, has been named as the Herbert T. Abelson Professor, and Dr. Godley, an expert in the field of inherited susceptibility to hematopoietic malignancies, has named as the Inaugural Hospira Foundation Professor in Oncology.

Dr. Arora is an academic hospitalist and medical educator who specializes in improving the learning environment for medical trainees and the quality, safety and experience of care delivered to hospitalized adults. She currently serves as the associate chief medical officer for the Clinical Learning Environment at UChicago Medicine and assistant dean for scholarship and discovery at the Pritzker School of Medicine.

Dr. Arora’s work bridges medical education and hospital leadership to transform learning and care delivered in teaching hospitals. She is an internationally recognized expert on patient handoffs in health care and also has extensive expertise using technology, such as social media, to improve medical education. She was named to the National Academy of Medicine in 2019.

Dr. Godley is an expert in the care and treatment of patients with diseases of the bone marrow, including leukemias, lymphomas and multiple myeloma. She also cares for patients undergoing stem cell transplantation and patients with benign hematologic conditions. She has a special interest in the molecular basis of bone marrow malignancies and is an active researcher in the field.

Dr. Godley seeks to improve health through a deeper understanding and appreciation of science by integrating knowledge about fundamental networks within cancer cells and by bringing novel insights into the pathophysiology of her patients’ diseases while offering them new treatment options. Her research focuses on the germline genetic mutations and acquired epigenetic modifications that drive oncogenesis, particularly for hematopoietic malignancies. She has established the clinical standard for germline predisposition testing for patients with personal and family histories of hematopoietic cancers. She also co-chairs several panels and workshops to establish standards for clinical laboratories, fosters learning and stimulates research on these diseases.

 

More